

Identification of Immunological Biomarkers of Atopic Dermatitis by Integrated Analysis to Determine Molecular Targets for Diagnosis and Therapy

Yixiu Zhong
Kaiwen Qin
Leqian Li
Huiye Liu
Zhiyue Xie
Kang Zeng

Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China

Purpose: Atopic dermatitis (AD) is a common chronic inflammatory skin disorder associated with immune dysregulation and barrier dysfunction. In this study, we investigated immunological biomarkers for AD diagnosis and treatment using CIBERSORT to identify immune cell infiltration characteristics.

Patients and Methods: Common differentially expressed genes (DEGs) of lesioned (LS) vs non-lesioned (NL) groups were obtained from public datasets (GSE140684 and GSE99802). We performed functional enrichment analysis and selected hub genes from the protein-protein interaction (PPI) network. The hub genes were then subjected to transcription factor (TF), microRNA (miRNA), long non-coding RNA (lncRNA), drug interaction, and protein subcellular localization analyses. We also performed correlation analysis on differentially expressed immune cells, TFs, and hub genes. Receiver operating characteristic (ROC) curve analysis and binomial least absolute shrinkage and selection operator (LASSO) regression analysis were employed to assess the expression of hub genes in the GSE99802, GSE140684, GSE58558, GSE120721, and GSE36842 datasets.

Results: We identified 238 common DEGs and 25 hub genes. Additionally, we predicted TFs, miRNAs, lncRNA, drugs, and protein subcellular localizations. The proportions of activated dendritic cells (DCs) and CD4⁺ memory T cells were relatively high in the LS skin. Expression levels of the TF FOXC1 were negatively correlated with target genes and the abundance of two immune cell types. The LASSO model showed that GZMB, CXCL1, and CD274 are candidate diagnostic biomarkers.

Conclusion: Our study suggests that downregulated expression of FOXC1 expression may enhance the levels of chemokines, chemokine receptors, T cell receptor signaling molecules, activating CD4⁺ memory T cells and DCs in AD.

Keywords: atopic dermatitis, CIBERSORT, immune infiltration, transcription factors, biomarkers

Introduction

Atopic dermatitis (AD) is a common chronic inflammatory skin disease, characterized by recurrent eczematous lesions and intense itching. AD is ranked as the leading cause of the global burden from skin inflammatory disease,¹ affecting approximately 10–30% of children and 2–10% of adults worldwide.² AD patients were divided into infantile AD, childhood AD and adult AD. Adult AD patients

Correspondence: Kang Zeng
Tel +862062787322
Email npfkzkl@126.com

Received: 26 July 2021
Accepted: 4 November 2021
Published: 15 November 2021



contain three forms, the persistent form of childhood-onset of AD, the relapsing form of childhood-onset of AD, and the adult-onset AD. Nummular eczema-like phenotype and prurigo nodularis-like pattern appeared to be more related to adult-onset AD, while lichenified/exudative flexural dermatitis was more common in childhood-onset AD.³ However, the mode of inheritance and genes involved in AD remain unclear. Currently, diagnosis relies exclusively on clinical features due to the lack of specific laboratory or histological findings.

In addition, conventional therapies were unsatisfactory for AD patients, due to the long-term side effects of glucocorticoid and immunosuppressant drugs. Recently, numerous monoclonal antibodies such as nemolizumab, blocking IL-31 receptor, dupilumab, blocking IL-4 receptor, lebrikizumab targeting IL-13 receptor have been widely used and proven effective in the treatment of AD. And new topical molecules such as JAK inhibitor, tofacitinib, phosphodiesterase 4 inhibitors, crisaborole and apremilast, and selective JAK1 and JAK2 inhibitor, baricitinib can also improve the clinical outcome of AD patients.⁴ Therefore, exploring specific targeting drugs opened a promising new era for AD treatment.

Immune cells, particularly dendritic cells (DCs) and CD4+ memory T cells, play key roles in AD progression. Because the immune response in AD involves functionally distinct cell types, it is necessary to assess and determine immune-infiltration changes specific to the condition to develop novel immunotherapeutic drugs that target various immune cells. As an analytical tool, CIBERSORT can be used to estimate the proportion of different immune cell types based on RNA-sequencing data.⁵ CIBERSORT contains 22 cell types, including B cells, T cells, monocytes, eosinophils, macrophages, natural killer cells, neutrophils, plasma cells, dendritic cells (DCs), and mast cells.⁶ The tool has been widely used to assess immune cell infiltrations in malignant tumors such as colorectal cancer and renal cell carcinoma.^{7,8} In the AD skin tissue, DCs require cytokines, cytokine receptors, and T cell receptor (TCR) signals to recognize and present antigens to naïve T cells. These processes induce adaptive immunity to cause skin inflammation and barrier dysfunction. Furthermore, the impaired skin barrier facilitates infiltration of foreign antigens (eg, food allergens) as well as activation of pattern recognition and innate immune receptors. Consequently, IgE- and FCεRI-bearing dermal DCs are activated and migrate to the regional lymph nodes, inducing Th2 differentiation and B-cell IgE skewing. Specific T-cell subsets

are recruited to the lesioned skin tissue, producing cytokines and chemokines. Both Th2 and Th22 (IL-22) cytokines inhibit epidermal differentiation and lipid synthesis, facilitating *Staphylococcus aureus* colonization and accelerating the so-called “AD march”.⁹ Although characterized by Th2 immune responses, AD is now considered a heterogeneous disease, with additional activation of Th22, Th17/IL23, and Th1 cytokine pathways.¹⁰ However, the immune landscape of AD has not been entirely revealed. Therefore, we used CIBERSORT to explore effective immunological biomarkers for the diagnosis and treatment of AD.

In particular, we explored the immune landscapes of lesioned (LS) tissue and non-lesioned (NL) tissue from patients with AD and used CIBERSORT to determine their differences. Common differentially expressed genes (DEGs), hub proteins and their transcription factors (TFs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) were analyzed using the GSE140684 and GSE99802 microarray datasets. Based on comprehensive bioinformatics analysis, we further aimed to investigate the molecular mechanisms underlying AD development and identify potential AD biomarkers ([Supplementary Figure 1](#)).

Materials and Methods

Microarray Data Processing and Identification of DEGs

From the GEO database, we obtained five expression profile datasets of AD, GSE140684, GSE99802, GSE58558, GSE120721 and GSE36842. 50 samples of GSE140684,¹¹ including 29 from LS tissue and 21 from NL tissue, 112 samples GSE99802,¹² including 59 from LS tissue and 53 from NL tissue, 35 samples GSE58558,¹³ including 18 from LS tissue and 17 from NL tissue, 30 samples GSE120721,¹⁴ including 15 from LS tissue and 15 from NL tissue, 16 samples GSE36842,¹⁵ including 8 from LS tissue and 8 from NL tissue were selected in this study.

The original expression matrix was processed and analyzed by R software. DEGs were screened out by using the function *lmFit* and *eBayes* in the *Limma* package.¹⁶ Genes with adjusted $P < 0.05$ and $\log_2FC > 1$, were considered as DEGs of GSE140684, while genes with adjusted $P < 0.05$ and $\log_2FC > 0.5$ were considered as DEGs of GSE99802. TB tools was used to present Heatmap and perform Venn

analysis to identify common DEGs from GSE99802 and GSE140684.¹⁷

Gene Set Enrichment Analysis

Gene set enrichment analysis (GSEA) is a widely used computational method for genome-wide expression matrix.¹⁸ In the present study, genetic information of GSE99802 and GSE140684 were uploaded to GSEA software (version 4.0.3). GSEA was performed to identify biological process (BP) Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways connected with AD. GSEA analysis was conducted according to default parameters. $P < 0.05$ was considered significant.

The enrichment analysis of DEGs was performed by using the clusterProfile package of R software and visualized by Hiplot (<https://hiplot.com.cn/>).¹⁹ KEGG pathways and GO terms with $P < 0.05$ were selected.

Protein-Protein Interaction (PPI) Analysis

In order to provide insights into the mechanisms of AD, DEGs were uploaded to STRING (<http://string-db.org>) to construct PPI network.²⁰ Cytoscape (version 3.8.0), an open-source bioinformatics software platform was used to visualize molecular interaction networks and select key nodes.²¹ CytoHubba, a Cytoscape plugin, ranked the top 25 genes as hub genes, according to Maximal Clique Centrality (MCC).²²

TFs-mRNA Interaction Analysis

JASPAR database was used to identify regulatory TFs that influence the hub genes at a transcriptional level.²³ Hub gene-TF regulatory network was constructed and visualized by the Cytoscape software. The correlation between these TFs and hub genes was evaluated by Pearson correlation coefficient.

miRNA-mRNA and miRNAs-lncRNAs Interaction Analysis

The miRNA-mRNA regulatory network was constructed via miRTarBase v8.0,²⁴ including experimentally supported miRNA-gene interactions, and was further processed with Cytoscape. Then, miRNAs targeting more than 3 genes were selected. Based on StarBase 2.0,²⁵ the upstream molecules lncRNAs of the selected miRNAs were predicted with CLIP-Data ≥ 7 , and were further analyzed by Cytoscape.

Cross-Validation of Candidate Biomolecules

DisGeNET is one of the largest publicly available platforms of genes and variants associated with human disease.²⁶ ImmPort is an open human immunology database for translational and clinical research.²⁷ In order to identify key genes and validate our workflow, we cross-checked the identified hub genes and TFs with DisGeNET and ImmPort. Then, we cross-checked the identified miRNAs by HMDD [22].

Drug-Hub Gene Interaction Analysis

To explore potential drugs for the treatment of AD, DrugBank database²⁸ was used to identify drug-hub gene interaction via NetworkAnalyst.²⁹ The identified target network was visualized by Cytoscape.

Prediction of Protein Subcellular Localization

We applied Cell-PLoc-2 to predict the subcellular localization of the proteins encoded by hub genes.³⁰ Cell-PLoc-2 is an improved online tool for predicting subcellular localization of proteins based on amino acid sequence.

Evaluation of Immune Cell Infiltration and Correlation Analysis of Immune Cell Infiltration Types and Hub Genes

To evaluate the abundance of infiltrating immune cells in LS skin and NL skin of AD, we used CIBERSORT gene signature file LM22, including neutrophils, dendritic cells (DCs), natural killer cells, macrophages, B cells, T cells, and subdivided resting and activated immune cell subtypes.⁶ CIBERSORT is based on linear support vector regression. Gene expression datasets GSE14064 and GSE99802 were processed and uploaded to CIBERSORT webservice portal (<http://cibersort.stanford.edu/>). P-value < 0.05 was set as cut-off criteria. Differentially expressed immune cells between the LS group and NL group were obtained. Pearson correlation coefficient analysis was conducted and visualized by Hiplot in order to explore the relationship between these different subpopulations of immune cells and hub genes.




Figure 1 Identification of DEGs in microarray datasets GSE140684 and GSE99802. **(A)** Heat map of top 20 down-regulated and up-regulated DEGs of GSE140684 **(B)** Heat map of top 20 down-regulated and up-regulated DEGs of GSE99802. **(C)** Volcano plot of the distributions of all DEGs of LS and NL samples of GSE140684 (adj. $P < 0.05$, $\log_{2}FC > 1$). **(D)** Volcano plot of the distributions of all DEGs of LS and NL samples of GSE99802 (adj. $P < 0.05$, $\log_{2}FC > 0.5$). Blue dots represent significantly down-regulated genes and red dots represent significantly up-regulated genes in LS samples. **(E)** Venn plot of common DEGs identified between two data sets. **Abbreviations:** FC, fold-change; DEGs, differentially expressed genes; NL, non-lesioned; LS, lesioned.

Construction of Least Absolute Shrinkage and Selection Operator (LASSO) Model and Receiver Operating Characteristic (ROC) Analysis

To select the best features for high-dimensional data, we applied LASSO with strong predictive value and low correlation. The expression profile of GSE99802 hub genes were extracted to construct LASSO model by glmnet (<https://CRAN.R-project.org/package=glmnet>), so as to distinguish LS skin from NL skin of AD. A model index was established using the regression coefficients

from the LASSO analysis to weight the expression value of the hub genes. Then, Hplot was used to conduct and perform ROC curve analysis in GSE140684, GSE99802, GSE58558, GSE120721, and GSE36842.³¹

Results

Identification of DEGs

Based on the sample information and data matrix, 551 and 445 genes were differentially expressed in LS and NL samples of GSE140684 (adj.P< 0.05, logFC>1) and GSE99802 (adj.P<0.05, logFC>0.5), respectively. The 20




Figure 2 GSEA-based KEGG analysis. (A) GSEA-based KEGG analysis of GSE140684. (B) GSEA-based KEGG analysis of GSE99802.

Abbreviations: GSEA, gene set enrichment analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes.

most up- and down-regulated gene heatmaps were visualized in volcano plots (Figure 1A–D). 238 DEGs common to both GSE140684 and GSE99802 were found (Figure 1E).

DEGs from LS Samples Were Mainly Enriched in the Cytokine-Cytokine Receptor Interaction Pathway and Immune Response

According to GSEA-based KEGG analysis, gene sets associated with the cytokine-cytokine receptor interaction and chemokine signaling significantly enriched in LS samples of the GSE140684 and GSE99802 datasets (Figure 2). In addition, GSEA-based GO biological analysis revealed that the most strongly enriched terms were regulation of immune responses, DCs, and CD4+ T cells (Table 1).

KEGG analysis of the 238 DEGs revealed numerous genes enriched in immune-related pathways (cytokine-cytokine receptors interaction, viral protein interaction with cytokine and cytokine receptor, cell adhesion molecules, chemokine signaling, IL-17 signaling, T cell receptor signaling, and NF-kappa signaling) (Figure 3A). Among these, the cytokine-cytokine receptor pathway was the most significantly enriched pathway with 28 associated genes, including TNFSF8, CCR5, CCR7, CSF2RA, FLT3, CXCL1, CXCL2, IL2RG, IL4R, IL7R, CXCL8, IL13RA2, LTB, PRLR, CCL8, CCL17, CCL19, CCL20, CCL22, CXCL1, IL18RAP, IL27RA, CXCR6, IL24, IL37, IL21R, IL26, and IL36G. BP analysis revealed that the DEGs were mainly related to T cell activation, positive regulation of cell-cell adhesion, leukocyte cell-cell adhesion, positive regulation of leukocyte cell-cell adhesion, neutrophil migration, positive regulation of T cell activation, and neutrophil chemotaxis (Figure 3B).

Proteomic Signatures in AD

To identify the core genes among the DEGs identified between LS and NL samples, we constructed the PPI network and obtained 198 nodes plus 762 edges (Figure 4A). A high MCC indicates that a given protein is clustered in the center of the network and plays an essential role. We identified 25 hub genes in the PPI, including SELL and SLAMF1; we then used the MCC to select genes for further analysis (Figure 4B). The hub genes were mainly related to the immune system, including cytokines, cytokine receptors, TCR signaling molecules, selectins, and integrins (Table 2).

Competing Endogenous RNA (ceRNA) Signatures

We constructed the miRNA-mRNA regulatory network (Figure 5A) and selected seven miRNAs (gene counts ≥ 3) to predict interacting lncRNAs (Figure 5B). Among these miRNAs, we further investigated the roles of hsa-mir-124-3p, hsa-mir-21-5p, and hsa-mir-155-5p in AD (Table 3).

Correlation Between TFs and Hub Genes

The TF-hub gene regulatory networks (Figure 6A) identified potential roles of STAT3, JUN, PPARG, and RELA in AD (Table 4). The TF that targeted the highest number of hub genes was FOXC1, which showed significantly downregulated expression in both datasets. We then analyzed correlations between FOXC1 and its targeted hub genes (CCL20, CXCL1, IL2RG, CCR7, CTLA4, CD2, SLAMF1, LCK, LCP2, and ICOS) in the GSE90882 and GSE140684 datasets. The FOXC1 expression level was negatively correlated with the production of chemokines (CCL20, CXCL1), cytokine receptors (IL2RG, CCR7), and TCR signaling molecules (CTLA4, CD2, SLAMF1, LCK, LCP2, ICOS) (Figure 6B). These significant correlations in two

Table 1 Significantly Enriched GSEA-Based GO Terms of Biological Process Related to Immune Cells and Responses with P-value <0.05 Were Screened Out

GO Terms Biological Process	ES ¹⁴⁰⁶⁸⁴	P ¹⁴⁰⁶⁸⁴	ES ⁹⁹⁸⁰²	P ⁹⁹⁸⁰²
Positive regulation of type 2 immune response	0.8292	0.0079	0.8890	0.0000
Regulation of Th 1 immune response	0.8161	0.0176	0.8871	0.0000
Regulation of Th 17 immune response	0.8651	0.0077	0.8535	0.0122
Positive regulation of CD4 $\alpha\beta$ T cell differentiation	0.8534	0.0038	0.8691	0.0000
Positive regulation of CD4 $\alpha\beta$ T cell activation	0.8511	0.0038	0.8658	0.0000
Dendritic cell chemotaxis	0.8288	0.0020	0.8812	0.0044
Dendritic cell migration	0.8009	0.0059	0.8392	0.0088
Dendritic cell activation	0.7739	0.0333	0.8291	0.0260




Figure 3 Enrichment analysis of the common DEGs identified from GSE140684 and GSE99802. **(A)** Top seven enriched KEGG terms. **(B)** Top seven enriched GO biological process terms.

Abbreviations: DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.




Figure 4 Identification of hub genes. **(A)** PPI network of the DEGs in Atopic dermatitis. The nodes indicate the DEGs and the edges indicate the interactions between two proteins. Medium confidence score was used for the construction of PPI networks. **(B)** Top 25 hub genes with MCC by CytoHubba plugin.

Abbreviations: PPI, protein-protein interaction; MCC, maximum correlation criterion.

independent datasets further indicated that these hub genes and FOXC1 play an indispensable role in AD development.

Drug Analysis

Seven hub genes (CCR5, CXCL8, MMP9, LCK, ITGAL, ITK, IL2RG) had interactions with 42 drugs for possible treatment (Figure 7A).

Employing Cell-PLoc-2, we identified the subcellular localization of proteins encoded by the 25 hub genes of AD. The proportions of hub proteins in different subcellular locations are displayed in Figure 7B. Notably, the hub nodes LCP2 and ITK displayed cytoplasm localization; CD2, ITGAX, and IKZF1 were localized in the nucleus; SELL, CTLA4, CD28, SLAMF1,

Table 2 Summary of Hub Proteins Identified from Protein-Protein Interactions Analysis of Encoded Differentially Expressed Genes in Atopic Dermatitis

Symbol	Name	Feature	Rank	Description
SELL	Selectin L	Candidate marker	1	Selectin family
CTLA4	Cytotoxic T-Lymphocyte	Afflicted with AD	2	TCR signaling Pathway
	Associated Protein 4			
IL7R	Interleukin 7 Receptor	Candidate marker	3	Antimicrobials/Cytokine Receptors/Interleukins Receptor
CD28	T-Cell-Specific Surface	Afflicted with AD	4	Antimicrobials/TCR signaling Pathway
	Glycoprotein CD28			
CD2	CD2 Molecule	Candidate marker	5	TCR signaling Pathway
SLAMF1	Signaling Lymphocytic	Candidate marker	6	NK Cell Cytotoxicity/TCR signaling Pathway
	Activation Molecule Family Member 1			
LCK	Lymphocyte Cell-Specific	Candidate marker	7	NK Cell Cytotoxicity/TCR signaling Pathway
	Protein-Tyrosine Kinase			
CD3E	CD3e Molecule	Candidate marker	8	TCR signaling Pathway
CD5	CD5 Molecule	Candidate marker	9	TCR signaling Pathway
GZMB	Granzyme B	Candidate marker	10	NK Cell Cytotoxicity
ITGAL	Integrin Subunit Alpha L	Candidate marker	11	NK Cell Cytotoxicity
CCR7	C-C Motif Chemokine Receptor 7	Candidate marker	12	Antimicrobials/Chemokine Receptors/Cytokine Receptors
IL2RG	Interleukin 2 Receptor Subunit Gamma	Candidate marker	13	Cytokine Receptors /Interleukins Receptor
ITGAX	Integrin Subunit Alpha X	Candidate marker	14	Integrin family
LCP2	Lymphocyte Cytosolic Protein 2	Candidate marker	15	NK Cell Cytotoxicity /TCR signaling Pathway
CCR5	C-C Motif Chemokine Receptor 5	Afflicted with AD	16	Antimicrobials/Chemokine Receptors/Cytokine Receptors
IKZF1	IKAROS Family Zinc Finger 1	Candidate marker	17	Transcription factor
CD274	CD274 Molecule	Candidate marker	18	TCR signaling Pathway
CXCL8	C-X-C Motif Chemokine Ligand 8	Afflicted with AD	19	Antimicrobials/Chemokines/Cytokines/Interleukins
CCL19	C-C Motif Chemokine Ligand 19	Candidate marker	20	Antimicrobials/Chemokines/Cytokines
ICOS	Inducible T Cell Costimulator	Afflicted with AD	21	TCR signaling Pathway
CCL20	C-C Motif Chemokine Ligand 20	Afflicted with AD	22	Antimicrobials/Chemokines/Cytokines
CXCL1	C-X-C Motif Chemokine Ligand 1	Afflicted with AD	23	Antimicrobials/Chemokines
ITK	IL2 Inducible T Cell Kinase	Afflicted with AD	24	TCR signaling Pathway
MMP9	Matrix Metalloproteinase 9	Afflicted with AD	25	Antimicrobials

CD3E, CD5, IL2RG, CCR5, and CD274 were localized in plasma membrane; and IL7R, ITGAL, CXCL8, CCL19, ICOS, CCL20, and CXCL1 were localized in the extracellular space.

Correlation Analysis Between Hub Gene Expression and Immune Cell Infiltration

Based on the CIBERSORT output results, we analyzed 42 (84%) samples from GSE99802, while excluding




Figure 5 Construction of ceRNA regulatory networks. **(A)** miRNA-mRNA regulatory network. Medium confidence score was used for the construction of regulatory networks. Genes are colored in blue, and node size is adjusted according to number of targeted miRNAs; miRNAs are colored in purple; miRNAs targeting more than two genes simultaneously are colored in red. **(B)** miRNA-LncRNA regulatory network. MiRNA with genes count ≥ 3 were screened to predict LncRNA with CLIP-Data ≥ 7 . **Abbreviations:** ceRNA, competing endogenous RNA; miRNA, micro-RNA; LncRNA, long non-coding RNA.

GSE140684 entirely because it contained 21 (42%) non-significant ($p > 0.05$) samples, which prevented performing an accurate analysis. The different populations of infiltrating immune cells in the LS and NL groups are presented using a violin plot in Figure 8A. Three types of immune cells (resting CD4⁺ memory T cells, activated CD4⁺ memory T cells, and DCs) were significantly differentially expressed in both datasets, and were specifically upregulated in the LS tissue.

To further explore the relationship between hub gene expression and immune cell infiltration, we analyzed whether the expressions of hub genes were correlated with the levels of resting and activated CD4⁺ memory T cells as well as activated DCs. The levels of activated and resting CD4⁺ memory T cells were moderately correlated with the expressions of chemokine-encoding genes (eg, CXCL8, CXCL1, CCL20) and cytokine receptor-encoding genes (eg, IL7R, IL2R, CCR5). CCL19 and

Table 3 Summary of miRNAs (Genes Count ≥ 3) of Regulatory Biomolecules of the Hub Genes in Atopic Dermatitis Identified from Hub Genes-miRNA s Interactions

Symbol	Feature	Genes Count	Mechanism
hsa-mir-26b-5p	Candidate marker	5	Unclear
hsa-mir-335-5p	Candidate marker	5	Unclear
hsa-mir-204-5p	Candidate marker	5	Unclear
hsa-mir-211-5p	Candidate marker	5	Unclear
hsa-mir-155-5p	Afflicted with AD	5	Promotion of Th17 differentiation, Inhibition of tight junction formation
hsa-mir-124-3p	Afflicted with AD	3	Inhibition of inflammatory responses
hsa-mir-21-5p	Afflicted with AD	3	Activation of Th2 inflammation

CCR7 expression levels were positively correlated with the levels of activated and resting CD4⁺ memory T cells, respectively. Additionally, expression levels of TCR signaling molecules (CTLA4, CD3E, SLAMF1, LCK, LCP2, ICOS, and ITK, but not CD274) were significantly correlated with the levels of activated and resting CD4⁺ memory T cells (Figure 8B). We also found a positive correlation between the levels of activated DCs and the expressions of all hub genes, except for CCL20.

Exploring Candidate Biomarkers by ROC Curves and LASSO Regression

The LASSO regression model was firstly constructed for the GSE99802 dataset (with the largest number of samples) to search for an optimal linear combination of hub genes that can be used to diagnose AD (Figure 9A). Six genes were selected with non-zero regression coefficients and $\lambda_{\min} = 0.0383513$. The LASSO regression model was established as follows: $\text{index} = \text{SELL} * 0.343074243 + \text{IL7R} * 0.004220025 + \text{CXCL1} * 0.165991590 + \text{CCR7} * 0.416155475 + \text{CCR5} * 0.007626045 + \text{CCL19} * 0.050059214$. Each hub gene and the LASSO model was evaluated according to the ROC curve in five cohorts (GSE99802, GSE140684, GSE58558, GSE120721, and GSE36842) (Figure 9B). The AUC of the LASSO model was in the range of 0.75–1.00. CD274, GZMB, and CXCL1 showed particularly high performance, with AUC values above 0.9 in GSE36842, GSE120721, and GSE120721, respectively, indicating their potential as biomarkers of AD.


Discussion

The multifactorial background of AD occasionally causes therapeutic failure, necessitating individualized treatment and new solutions. One recommendation is to find a method that can distinguish patients with AD

according to various characteristics such as disease severity, biomarkers, and immunological polarization (ie, phenotypes, immunotypes).¹⁰ This strategy would allow for specific treatments to different forms of AD. Toward this end, in this study, we employed CIBERSORT to identify novel biomarkers and immunotypes that can be used to distinguish patients with AD. Enrichment analysis revealed AD-associated genes were mainly related to the immune response and cytokine interactions. Moreover, our results suggest that inhibition of the TF FOXC1 might upregulate hub genes, including those encoding cytokines, cytokine receptors, and TCR signaling molecules, to promote antigen presentation and activation of DCs. Surface receptors and TCR signaling molecules of CD4⁺ T cells can recognize antigens presented by DCs and initiate their differentiation into Th2 cells, causing local inflammation, epidermal dysfunction, and tissue remodeling and fibrosis, thus contributing to AD pathogenesis. In addition, the LASSO regression model of hub genes can be used to identify diagnostic biomarkers.

Our exploration of AD-related biological processes and pathways began with GSEA-based GO and KEGG pathway analyses. We found that AD-affected tissues were enriched in immune cells (CD4⁺ T cells and DCs), cytokine-cytokine receptors, as well as chemokine and TCR signaling pathways. It is well recognized that AD is a Th2/Th22-dominant disease, regulated by DC-induced T-cell polarization and recruitment of specific T-cell subsets by chemokines.³² Th17 and Th1 skewing also plays a role in causing AD.³³ Th2 cells release cytokines such as IL-4, IL-5, and IL-13, leading to elevated IgE production that increases skin inflammation and aggravates the skin barrier defect in AD.³⁴

A



B




Figure 6 Construction of TF regulatory networks and correlation analysis. **(A)** TF-mRNA regulatory networks. Medium confidence score was used for the construction of regulatory networks. **(B)** Correlation analysis between TF FOXC1 and targeted genes. **Abbreviation:** TF, transcription factor.

Table 4 Summary of TFs (Genes Count ≥5) of Regulatory Biomolecules of the Hub Genes in Atopic Dermatitis Identified from Hub Genes-TFs Interactions

Symbol	Name	Feature	Genes Count
FOXC1	Forkhead box C1	Candidate marker	16
GATA2	GATA binding protein 2	Candidate marker	15
YY1	YY1 transcription factor	Candidate marker	11
FOXL1	Forkhead box L1	Candidate marker	9
POU2F2	POU class 2 homeobox 2	Afflicted with AD	8
NFIC	Nuclear factor I C,	Candidate marker	7
HINFP	Histone H4 transcription factor	Candidate marker	6
RUNX2	RUNX family transcription factor 2	Afflicted with AD	6
MEF2A	Myocyte enhancer factor 2A	Candidate marker	5
STAT3	Signal transducer and activator of transcription 3	Candidate marker	5
JUN	Jun proto-oncogene	Candidate marker	5
PPARG	Peroxisome proliferator activated receptor gamma	Afflicted with AD	5
RELA	RELA proto-oncogene, NF-KB subunit	Afflicted with AD	5

These results were consistent with previous research and emphasized the important role of Th17 and Th1 polarization, apart from Th2/Th22 axis.

MicroRNAs are small endogenous non-coding RNAs that bind to the 3' untranslated region of genes and regulate gene expression through degrading or inhibiting the translation of target genes.³⁵ Our results identified several hub genes, miRNAs, confirmed by previous research. AD is characterized by impaired skin barrier and chronic inflammation.³⁶ MMP-9, as broad-spectrum protease, can break down a range of matrix and other

proteins, causing substantial tissue damage and barrier dysfunction of AD pathology.³⁷ Elevated level of CCR5 in AD induced chronic inflammation, impairing the skin of AD.³⁸ Additionally, by targeting the TF PU.1, microRNA-155 regulates DC-associated Th2 responses and controls allergic inflammation in mice.³⁹ Our study indicated these molecules were worthy of further exploration and might act as promising therapeutic targets.

Then, we used CIBERSORT to estimate the composition of immune cells and further correlate these cells with hub




Figure 7 Construction of protein-drug interaction network and subcellular localization. (A) Protein-drug interaction network of hub genes. (B) The distribution and percentages of the subcellular localization of the proteins encoded by hub genes.




Figure 8 Violin plot of immune cell composition between LS and NL tissue and correlation analysis between immune cells and hub genes. **(A)** The violin plot indicates the composition of 22 immune cells between LS and NL tissue in GSE140684 with CIBERSORT $p < 0.05$ for all eligible samples. The blue violin plot indicates NL tissue, and the red violin plot represents LS tissue. **(B)** Correlation analysis between differentially expressed immune cells and hub genes.

Abbreviations: NL, non-lesioned; LS, lesioned.

genes. Among the hub genes, cytokine-, cytokine-receptor-, and TCR-encoding genes were positively associated with infiltration of CD4+ memory T cells and activated DCs. Activated DCs can migrate to the regional lymph nodes, where they induce Th2 production and subsequent B-cell IgE switching. We found that activated DCs were positively correlated with the hub genes CCR5, CXCL1, and CXCL8. It was reported that CCL19 binds to CCR7 of DCs in the AD LS skin, leading to DC activation and Th2 polarization.⁴⁰ Additionally, DCs can promote cancer progression via CXCL1 and aggravate CXCL8 in chronic obstructive pulmonary disease.^{41,42} Together with these findings, our results might suggest that activated DCs could release CXCL1 and

CXCL8 to recruit neutrophils and cause skin inflammation in AD. Besides, activated DCs are positively correlated with TCR signaling molecules, suggesting that DCs upregulate these molecules and promote T cell differentiation, thereby impairing epidermal integrity and causing cutaneous inflammation.

Following antigen stimulation, T cells persist as effector memory T cells and central memory T cells in the lymph nodes and peripheral tissues.⁴³ Antigen recognition by TCR and interaction of inflammatory cytokines such as IL-2 with cytokine receptors are required for the generation and maintenance of tissue resident memory (TRM) T cells. IL7R and IL2RG can bind to IL-2,




Figure 9 Construction of LASSO regression model and ROC curves of hub genes in five cohorts. **(A)** The left plot indicates binomial deviance of different numbers of variables revealed by the LASSO regression model for GSE99802. The red dots represent the value of binomial deviance; the grey lines represent the SE; the vertical dotted lines represent optimal values by the minimum criteria and 1-SE criteria. “Lambda” is the tuning parameter. **(B)** The ROC curves of LASSO regression model (SELL*0.343074243+IL7R*0.004220025+CXCL1*0.165991590+CCR7*0.416155475 +CCR5*0.007626045+ CCL19*0.050059214) and top 5 genes in 5 cohorts (GSE99802, GSE140684, GSE58558, GSE120721, GSE36842).

Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic; SE, Standard error.

promoting the generation of CD4+ memory T cells.⁴⁴ Additionally, CCR5+ TRM cells can differentiate into Th17 and Th1 cells.⁴⁵ CCL19 promotes the differentiation of CCR7+ CD4+ memory T cells into Th2 subsets,⁴⁶ whereas CCL20 induces CD4+ memory T cell

differentiation into Th17 cells, leading to increased CXCL1 and CXCL8 production.⁴⁷ In addition, CD4+ memory T cell numbers are significantly related to TCR molecules (except for CD274); antigen recognition of TCRs is essential for CD4+ T cell differentiation into

memory subsets.⁴⁸ Our findings firstly suggest that CD4 + memory T cells might cause epidermal barrier dysfunction and contribute to AD by impairing intercellular cohesion and integrity, and disturbing keratinocyte differentiation.

Correlation analysis between differentially expressed TF FOXC1 and immune cell-related hub genes revealed important TFs that regulate hub gene expression, thus enhancing our understanding of AD pathogenesis. FOXC1, a member of the forkhead box TF family, is necessary for human keratinocyte terminal differentiation.⁴⁹ Previous research showed that CCL20 might induce the differentiation of CD4+ memory T cells into Th17 cells, attracting neutrophils, DCs, and more T lymphocytes to perpetuate skin inflammation. CCL19 might activate DCs and CD4+ memory T cells, leading to Th2 polarization in AD lesions. Our results suggest that FOXC1 might play a role in AD by upregulating the production of cytokines, cytokine receptors, and TCR signals. However, these conclusions require further investigation and confirmation.

We applied ROC analysis to evaluate single hub genes or LASSO linear models. The model consists of SELL, IL7R, CXCL1, CCR7, CCR5, and CCL19; however, three single genes (GZMB, CD274, and CXCL1) showed great diagnostic value in skin tissue.

Our study possesses several strengths, but also some limitations. We applied several novel analytic bioinformatic approaches on micro-array data of different datasets. The results were cross validated by DisGeNet and HMDD. A LASSO model was constructed based on one dataset and validated by four external datasets. However, we did not carry out experiments to validate the results. In order to better illustrate the key link between LS and NLI skin of AD patients, we did not include healthy controls in this study and ignore the basal genetic difference between individual. Therefore, a larger cohort, including healthy controls and more functional experiments are required to confirm the data.

Conclusion

In summary, our study employed next generation sequencing method to explore the differentially expressed genes of AD. Cibersort and LASSO model were applied to evaluate immune landscapes and diagnostic values of these genes in AD, respectively. A series of novel potential biomarkers, including immunological hub genes, TFs, miRNAs, and

lncRNAs, were identified as candidate biomarkers and promising therapeutic targets in the prediction and diagnosis of AD. And the specific molecular function of these molecules needs to be further investigated.

Ethics Approval and Consent to Participate

According to the guidelines of Medical Ethics committee of NanFang hospital of Southern Medical University, research on public resources, including previous data, file, record, specimen were exempt from approval. Our study is based on public database, GEO. The patients involved in the database have obtained ethical approval. Users can download relevant data for free for research and publish relevant articles, so there is no ethical issues.

Acknowledgments

This work was supported by the National Science Foundation of China [grant number 82073464].

Disclosure

The authors report no conflicts of interest in this work.

References

1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet*. 2020;396(10247):345–360. doi:10.1016/S0140-6736(20)31286-1
2. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multi-country cross-sectional surveys. *Lancet*. 2006;368(9537):733–743. doi:10.1016/S0140-6736(06)9283-0
3. Nettis E, Ortoncelli M, Pellacani G, et al. A Multicenter Study on the prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. *J Investig Allergol Clin Immunol*. 2020;30:448–450. doi:10.18176/jiaci.0519
4. Dattola A, Bennardo L, Silvestri M, Nisticò SP. What's new in the treatment of atopic dermatitis? *Dermatol Ther*. 2019;32:e12787. doi:10.1111/dth.12787
5. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. *Methods Mol Biol*. 2018;1711:243–259.
6. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods*. 2015;12:453–457.
7. Ge P, Wang W, Li L, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. *Biomed Pharmacother*. 2019;118:109228. doi:10.1016/j.biopha.2019.109228
8. Zhu G, Pei L, Yin H, et al. Profiles of tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications. *Oncol Lett*. 2019;18:5235–5242.
9. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. *J Allergy Clin Immunol*. 2017;139(6):1723–1734. doi:10.1016/j.jaci.2017.04.004

10. Klonowska J, Gleń J, Nowicki R, Trzeciak M. New cytokines in the pathogenesis of atopic dermatitis—new therapeutic targets. *Int J Mol Sci.* 2018;19(10):3086. doi:10.3390/ijms19103086
11. Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. *Exp Dermatol.* 2017;26(1):28–35. doi:10.1111/exd.13112
12. Brunner PM, Pavel AB, Khattri S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. *J Allergy Clin Immunol.* 2019;143(1):142–154. doi:10.1016/j.jaci.2018.07.028
13. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. *J Allergy Clin Immunol.* 2014;133(6):1626–1634. doi:10.1016/j.jaci.2014.03.003
14. Esaki H, Ewald DA, Ungar B, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. *J Allergy Clin Immunol.* 2015;135(1):153–163. doi:10.1016/j.jaci.2014.10.037
15. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol.* 2012;130(6):1344–1354. doi:10.1016/j.jaci.2012.07.012
16. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43(7):e47. doi:10.1093/nar/gkv007
17. Chen C, Chen H, Zhang Y, et al. TBtools: an integrative toolkit developed for interactive analyses of big biological data. *Mol Plant.* 2020;13(8):1194–1202. doi:10.1016/j.molp.2020.06.009
18. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
19. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS.* 2012;16(5):284–287. doi:10.1089/omi.2011.0118
20. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res.* 2012;41(D1):D808–D815. doi:10.1093/nar/gks1094
21. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. *Bioinformatics.* 2011;27(3):431–432. doi:10.1093/bioinformatics/btq675
22. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol.* 2014;8(Suppl 4):S11. doi:10.1186/1752-0509-8-S4-S11
23. Khan A, Fornes O, Stigliani A, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids Res.* 2018;46:D260–D266. doi:10.1093/nar/gkx1126
24. Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. *Nucleic Acids Res.* 2018;46:D296–D302. doi:10.1093/nar/gkx1067
25. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. *Nucleic Acids Res.* 2014;42:D92–D97. doi:10.1093/nar/gkt1248
26. Piñero J, Ramirez-Anguaita JM, Sañch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic Acids Res.* 2020;48:D845–D855.
27. Bhattacharya S, Dunn P, Thomas CG, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. *Sci Data.* 2018;5:180015. doi:10.1038/sdata.2018.15
28. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.* 2018;46(D1):D1074–D1082. doi:10.1093/nar/gkx1037
29. Xia J, Gill EE, Hancock RE. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. *Nat Protoc.* 2015;10:823–844. doi:10.1038/nprot.2015.052
30. Chou KC, Shen HB. Cell-PLoc: a package of web servers for predicting subcellular localization of proteins in various organisms. *Nat Protoc.* 2008;3:153–162. doi:10.1038/nprot.2007.494
31. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw.* 2010;33:1–22. doi:10.18637/jss.v033.i01
32. Fujita H, Shemer A, Suárez-Fariñas M, et al. Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. *J Allergy Clin Immunol.* 2011;128:574–582. doi:10.1016/j.jaci.2011.05.016
33. Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is T(H)2 but also T(H)17 polarized in skin. *J Allergy Clin Immunol.* 2016;138:1639–1651. doi:10.1016/j.jaci.2016.07.013
34. Liu F, Goodarzi H, Chen H, Misery L. IgE, mast cells, and eosinophils in atopic dermatitis. *Clin Rev Allerg Immunol.* 2011;41:298–310. doi:10.1007/s12016-011-8252-4
35. Ragusa M, Barbagallo C, Brex D, et al. Molecular crosstalk among noncoding RNAs: a new network layer of genome regulation in cancer. *Int J Genomics.* 2017;2017:4723193. doi:10.1155/2017/4723193
36. Morelli P, Gaspari M, Gabriele C, et al. Proteomic analysis from skin swabs reveals a new set of proteins identifying skin impairment in atopic dermatitis. *Exp Dermatol.* 2021;30:811–819. doi:10.1111/exd.14276
37. Harper JI, Godwin H, Green A, et al. A study of matrix metalloproteinase expression and activity in atopic dermatitis using a novel skin wash sampling assay for functional biomarker analysis. *Br J Dermatol.* 2010;162:397–403. doi:10.1111/j.1365-2133.2009.09467.x
38. Kato Y, Pawankar R, Kimura Y, Kawana S. Increased expression of RANTES, CCR3 and CCR5 in the lesional skin of patients with atopic eczema. *Int Arch Allergy Immunol.* 2006;139(3):245–257. doi:10.1159/000091170
39. Ma L, Xue HB, Wang F, Shu CM, Zhang JH. MicroRNA-155 may be involved in the pathogenesis of atopic dermatitis by modulating the differentiation and function of T helper type 17 (Th17) cells. *Clin Exp Immunol.* 2015;181:142–149. doi:10.1111/cei.12624
40. He H, Suryawanshi H, Morozov P, et al. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. *J Allergy Clin Immunol.* 2020;145:1615–1628. doi:10.1016/j.jaci.2020.01.042
41. Hsu YL, Chen YJ, Chang WA, et al. Interaction between tumor-associated dendritic cells and colon cancer cells contributes to tumor progression via CXCL1. *Int J Mol Sci.* 2018;19:2427.
42. Gianello V, Salvi V, Parola C, et al. The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells. *Biochem Pharmacol.* 2019;163:371–380. doi:10.1016/j.bcp.2019.03.006
43. Sallusto F, Cassotta A, Hoces D, Foglierini M, Lanzavecchia A. Do memory CD4 T cells keep their cell-type programming: plasticity versus fate commitment? T-cell heterogeneity, plasticity, and selection in humans. *Cold Spring Harb Perspect Biol.* 2018;10:a029421. doi:10.1101/cshperspect.a029421
44. Dooms H, Wolslegel K, Lin P, Abbas AK. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. *J Exp Med.* 2007;204:547–557. doi:10.1084/jem.20062381
45. Woodward DA, Roozen HN, Dufort MJ, et al. The human tissue-resident CCR5(+) T cell compartment maintains protective and functional properties during inflammation. *Sci Transl Med.* 2019;11:eaaw8718.

46. Colantonio L, Recalde H, Sinigaglia F, D'Ambrosio D. Modulation of chemokine receptor expression and chemotactic responsiveness during differentiation of human naive T cells into Th1 or Th2 cells. *Eur J Immunol.* 2002;32:1264–1273.
47. Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and keratinocytes in psoriasis. *Int J Mol Sci.* 2020;21:1275.
48. Schreiner D, King CG. CD4+ memory T cells at home in the tissue: mechanisms for health and disease. *Front Immunol.* 2018;9. doi:10.3389/fimmu.2018.02394
49. Bin L, Deng L, Yang H, et al. Forkhead box C1 regulates human primary keratinocyte terminal differentiation. *PLoS One.* 2016;11:e167392. doi:10.1371/journal.pone.0167392

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>